| Texto completo | |
| Autor(es): Mostrar menos - |
dos Santos, Jean Leandro
;
Moreira, Vanessa
;
Campos, Michel Leandro
;
Chelucci, Rafael Consolin
;
Barbieri, Karina Pereira
;
Maggio de Castro Souto, Pollyana Cristina
;
Matsubara, Marcio Hideki
;
Teixeira, Catarina
;
Bosquesi, Priscila Longhin
;
Peccinini, Rosangela Goncalves
;
Chin, Chung Man
Número total de Autores: 11
|
| Tipo de documento: | Artigo Científico |
| Fonte: | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES; v. 13, n. 11, p. 16-pg., 2012-11-01. |
| Resumo | |
Long-term nonsteroidal anti-inflammatory drugs (NSAIDs) therapy has been associated with several adverse effects such as gastric ulceration and cardiovascular events. Among the molecular modifications strategies, the prodrug approach is a useful tool to discover new safe NSAIDs. The 1-(2,6-dichlorophenyl)indolin-2-one is a diclofenac prodrug which demonstrated relevant anti-inflammatory properties without gastro ulceration effect. In addition, the prodrug decreases PGE(2) levels, COX-2 expression and cellular influx into peritoneal cavity induced by carrageenan treatment. Preliminary pharmacokinetic studies have shown in vivo bioconversion of prodrug to diclofenac. This prodrug is a new nonulcerogenic NSAID useful to treat inflammatory events by long-term therapy. (AU) | |
| Processo FAPESP: | 10/12495-6 - Otimização, síntese e avaliação farmacológica de novos candidatos a fármacos para tratamento dos sintomas da anemia falciforme |
| Beneficiário: | Jean Leandro dos Santos |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |
| Processo FAPESP: | 09/12664-5 - Farmacocinética pré-clínica do composto 1-(2,6-diclorofenil)indolin-2-ona (DICCIC), candidato a pró-fármaco, com propriedades anti-inflamatórias |
| Beneficiário: | Michel Leandro de Campos |
| Modalidade de apoio: | Bolsas no Brasil - Mestrado |